Switching to Lurasidone Helped Patients With Bipolar Disorder Shed Antipsychotic Weight Gain

For many people living with bipolar disorder, the drugs that steady their moods can quietly sabotage their bodies. Antipsychotic medications, a cornerstone of long-term treatment, are notorious for driving up body weight, and the resulting metabolic burden often pushes patients to abandon the very therapy that keeps them well. A new multicenter study from Korea now offers a cautiously encouraging answer: when patients troubled by antipsychotic-induced weight gain were switched to lurasidone, an atypical antipsychotic known for its weight-sparing profile, they lost on average about two kilograms over sixteen weeks, while their depressive symptoms improved and side effects remained rare and mild.

The research, published in BMC Psychiatry, was conducted across twelve outpatient psychiatric clinics and followed 155 adults with bipolar disorder who had been taking aripiprazole, quetiapine, or olanzapine for at least eight weeks. All of them had gained weight on those medications, and all were switched to lurasidone because of it. To keep the analysis clean, the investigators excluded anyone who stopped lurasidone or moved entirely to another antipsychotic within the first eight weeks, ensuring that the patients being measured had genuinely stayed on the new drug through the critical early period of treatment change.

The primary endpoint was simple and clinically meaningful: the change in body weight from the moment of switching to sixteen weeks later. Using a non-parametric statistical test appropriate for weight data that do not follow a neat bell curve, the researchers found that mean body weight fell from 74.49 kilograms at baseline to 72.43 kilograms at week sixteen. That difference of 2.06 kilograms came with a 95 percent confidence interval stretching from 2.50 kilograms down to 1.62 kilograms, and the probability that such a change arose by chance was reported as less than one in ten thousand. The median weight change was 2.0 kilograms, with the middle half of patients losing between 0.75 and 3.0 kilograms, indicating that the benefit was not confined to a handful of exceptional responders.

Body mass index told the same story. Average BMI declined from 27.03 to 26.28 kilograms per square meter, again with a p value below 0.0001, a shift large enough to matter at the population level even if it does not yet rescue most individual patients from the overweight range. Perhaps most striking was a descriptive post hoc finding: forty patients, or 25.8 percent of the cohort, achieved a weight reduction of at least five percent, the threshold clinicians typically regard as the minimum for meaningful cardiometabolic benefit. A quarter of patients crossing that line, in a real-world outpatient setting, is a notable result for a simple medication switch.

The benefits were not limited to the bathroom scale. Depressive symptom severity, measured with the 17-item Hamilton Depression Rating Scale, improved by an average of 5.36 points over the sixteen weeks, while global illness severity on the Clinical Global Impression-Severity scale dropped by 0.80 points, both statistically robust changes. This dual effect matters because lurasidone was designed with bipolar depression in mind; it carries established efficacy for the depressive phase of the illness, which is often the most disabling and prolonged component of bipolar disorder. A drug that lightens both mood symptoms and metabolic load addresses two of the biggest drivers of treatment non-adherence at once.

Safety data reinforced the picture. Treatment-emergent adverse events were recorded in only five patients, or 3.2 percent of the cohort, and every one of those events was judged mild. In a field where switching medications often triggers withdrawal effects, symptom flares, or new side-effect burdens, the low rate of recorded problems in this selected group suggests the transition to lurasidone was, for most patients who stayed on it, remarkably well tolerated. The authors stress, however, that the design itself filtered for tolerability: patients who abandoned lurasidone early were excluded, so the study speaks to those who persist with the switch rather than to everyone who attempts one.

That caveat sits at the heart of how these findings should be read. This was a retrospective observational study of a selected follow-up cohort, not a randomized controlled trial. Patients were chosen precisely because they had gained weight on their prior antipsychotic and were motivated or clinically directed to change, and those who stayed on lurasidone for the full observation window may differ systematically from those who did not. Without a control group, some of the weight loss could reflect behavioral changes that accompany a medication switch, increased clinical attention, or regression toward the mean after a period of weight gain. The authors themselves describe the post-switch weight trajectories as descriptive and explicitly call for prospective controlled evaluation.

Even with those limitations, the study fills a genuine gap. Lurasidone’s favorable metabolic profile has been established in registration trials, but real-world evidence in patients switched specifically because of antipsychotic-induced weight gain has been thin, particularly for bipolar disorder as opposed to schizophrenia. The subgroup findings add texture: weight decreases were observed across all three prior medication groups, including the 129 patients who switched from aripiprazole, a drug already considered relatively weight-neutral. That 83.2 percent of the cohort came from aripiprazole makes the consistency of the effect across subgroups especially informative, hinting that lurasidone’s metabolic advantage may be apparent even against a comparatively benign starting point.

The clinical implications reach beyond any single prescription. Antipsychotic-induced weight gain is one of the most persistent obstacles in psychiatry, quietly converting an effective psychiatric treatment into a risk factor for diabetes, hypertension, and cardiovascular disease, the conditions that ultimately shorten the lives of people with severe mental illness by years to decades. Strategies to counter it, from lifestyle programs to adjunctive weight-loss medications, exist but add complexity and cost. A straightforward switch to an efficacious, weight-sparing agent offers an appealingly simple lever, and the Korean data suggest that in ordinary clinic conditions that lever can move both weight and mood in the right direction within four months.

The study was investigator-initiated and partially funded by Bukwang Pharmaceutical, with the funder excluded from design, analysis, interpretation, and the decision to submit, and the authors had unrestricted access to the data. Those disclosures, together with the open-access publication, allow independent scrutiny of a result that will inevitably attract attention from clinicians weighing medication choices for weight-sensitive patients. For now, the message is measured but hopeful: in this carefully characterized Korean cohort, switching to lurasidone for antipsychotic-induced weight gain was followed by modest, statistically convincing weight loss, meaningful improvement in depressive symptoms, and very few adverse events. Whether the same trajectory holds for unselected patients over longer horizons is the question that prospective controlled trials, which the authors themselves now call for, will need to answer.

Subject of Research: Body weight and metabolic outcomes after switching to lurasidone for antipsychotic-induced weight gain in bipolar disorder

Article Title: Body weight changes after switching to lurasidone for antipsychotic-induced weight gain in bipolar disorder: a multicenter retrospective study of a selected follow-up cohort

Article References: Kim, Y.-C., Han, J.-W., Jang, W.-S., Kim, S.-W., Kwak, K.-H., Kwon, S.-J., Kwon, Y.-D., Na, Y.-S., Shin, H.-S., Shin, Y.-S., Song, H.-R., Song, M.-K., & Kim, D.-W. (2026). Body weight changes after switching to lurasidone for antipsychotic-induced weight gain in bipolar disorder: a multicenter retrospective study of a selected follow-up cohort. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08642-5

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08642-5

Keywords: bipolar disorder, lurasidone, antipsychotic-induced weight gain, drug switching, psychopharmacology, body mass index, retrospective study, BMC Psychiatry, weight management, cardiometabolic health, depressive symptoms, Korea